Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Coeptis Therapeutics Holdings, Inc. (COEP : NSDQ)
 
 • Company Description   
Coeptis Therapeutics Holdings Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals Inc., is a biopharmaceutical company developing innovative cell therapy platforms for cancer. Coeptis Therapeutics Holdings Inc., formerly known as Bull Horn Holdings Corp., is based in WEXFORD, Pa.

Number of Employees: 7

 
 • Price / Volume Information   
Yesterday's Closing Price: $9.50 Daily Weekly Monthly
20 Day Moving Average: 35,865 shares
Shares Outstanding: 3.51 (millions)
Market Capitalization: $33.38 (millions)
Beta: -0.63
52 Week High: $13.70
52 Week Low: $2.31
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 13.10% 8.86%
12 Week -5.00% -20.09%
Year To Date 72.73% 61.76%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
105 BRADFORD ROAD SUITE 420
-
WEXFORD,PA 15090
USA
ph: 724-934-6467
fax: -
ir@coeptistx.com https://coeptistx.com
 
 • General Corporate Information   
Officers
David Mehalick - Chief Executive Officer; Chairman and President
Daniel Yerace - Director and Vice President of Operations
Brian Cogley - Chief Financial Officer
Christine Sheehy - Vice President of Compliance and Secretary
Christopher Calise - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 19207A207
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/21/25
Share - Related Items
Shares Outstanding: 3.51
Most Recent Split Date: 12.00 (0.05:1)
Beta: -0.63
Market Capitalization: $33.38 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/21/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.28
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 30.62%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -282.39
12/31/24 - -588.10
ROA
06/30/25 - -
03/31/25 - -127.23
12/31/24 - -167.62
Current Ratio
06/30/25 - -
03/31/25 - 0.82
12/31/24 - 0.23
Quick Ratio
06/30/25 - -
03/31/25 - 0.82
12/31/24 - 0.23
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -17,931.75
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 2.22
12/31/24 - 1.61
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.02
12/31/24 - 0.04
Debt-to-Capital
06/30/25 - -
03/31/25 - 1.97
12/31/24 - 3.73
 

Powered by Zacks Investment Research ©